Galera Therapeutics, Inc.
GRTX
$0.02
$0.00-6.62%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 54.18% | 54.72% | 64.66% | 67.91% | 71.85% |
| Total Depreciation and Amortization | -100.00% | -97.93% | -95.56% | -92.28% | 235.71% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -45.75% | 4.13% | -34.79% | -47.23% | -64.88% |
| Change in Net Operating Assets | 78.08% | 70.03% | 71.01% | 27.30% | -1,102.45% |
| Cash from Operations | 65.57% | 72.18% | 74.74% | 72.92% | 59.65% |
| Capital Expenditure | -- | -- | -- | -- | 82.00% |
| Sale of Property, Plant, and Equipment | -100.00% | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -84.76% |
| Cash from Investing | -101.26% | -100.32% | -100.21% | -100.17% | -84.75% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -37.01% | -54.99% | -93.49% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 200.00% |
| Cash from Financing | 1,331.90% | 50.26% | -23.05% | -92.94% | -100.67% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 75.07% | 59.43% | 44.75% | -171.50% | -237.13% |